Characterization of Differentially Abundant Proteins Among Leishmania (Viannia) braziliensis Strains Isolated From Atypical or Typical Lesions

Bárbara B. Esteves 1, Marcella N. Melo-Braga 2, Vladimir Gorshkov 3, Thiago Verano-Braga 4, Martin R. Larsen 9, Célia M. F. Gontijo 5, Patricia F. Quaresma 6 and Helida M. Andrade 1*

1 Laboratório de Leishmanioses, Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 2 Laboratório de Biologia Sintética e Biomiméticos, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 3 Departamento de Bioquímica and Molecular Biology, University of Southern Denmark, Odense, Denmark, 4 Núcleo de Proteomica Funcional, Departamento de Fisiologia e Biofísica, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 5 Study Group in Leishmaniosis, Instituto René Rachou (FRR) –Fundação Oswaldo Cruz (FIOCRUZ/MG) Belo Horizonte, Belo Horizonte, Brazil, 6 Departamento de Microbiologia Imunologia e Parasitologia, Universidade Federal de Santa Catarina, Florianópolis, Brazil

Leishmania (Viannia) braziliensis is the main etiological agent of cutaneous and mucocutaneous leishmaniasis in Latin America. Non-ulcerated atypical tegumentary leishmaniasis cases caused by L. braziliensis have been reported in several regions of the American continent, including the Xacriabá indigenous reserve in São João das Missões/Minas Gerais, Brazil. Parasites isolated from these atypical clinical lesions are resistant to antimony-based therapeutics. In the present study, proteins displaying differential abundance in two strains of L. braziliensis isolated from patients with atypical lesions compared with four strains isolated from patients with typical lesions were identified using a quantitative proteomics approach based on tandem mass tag labeling (TMT) and mass spectrometry. A total of 532 (P<0.05) differentially abundant proteins were identified (298 upregulated and 234 downregulated) in strains from atypical lesions compared to strains from typical lesions. Prominent positively regulated proteins in atypical strains included those that may confer greater survival inside macrophages, proteins related to antimony resistance, and proteins associated with higher peroxidase activity. Additionally, we identified proteins showing potential as new drug and vaccine targets. Our findings contribute to the characterization of these intriguing L. braziliensis strains and provide a novel perspective on Atypical Cutaneous Leishmaniasis (ACL) cases that have been associated with therapeutic failures.

Keywords: Leishmania braziliensis, atypical wounds, proteome, abundance, TMT, antimony resistance
1 INTRODUCTION

In different parts of the world, authors have referred to Atypical Cutaneous Leishmaniasis (ACL) cases as sporotrichoid, reported in Pakistan, but no Leishmania species was identified (Iftikhar et al., 2003), erysipeloid, reported in Anatolia, Turkey, also unidentified species of Leishmania (Karincagolu et al., 2004), recidiva cutis, caused by L. panamensis (Calvopina et al., 2005) or zosteriform, reported in Iran (Omidian and Mapar, 2006). On the other hand, Leishmania (Viannia) braziliensis is an important Leishmania species that circulates in several North and South American countries. This species can cause a wide spectrum of clinical manifestations ranging from single and typical lesions with a granular background and raised edges, known as cutaneous leishmaniasis (CL), to the involvement of nasal and oral mucous membranes, also known as the cutaneous-mucosal or mucosal form (Lainson and Shaw, 1998). The spectrum of injuries caused by L. braziliensis also includes reports of atypical cutaneous leishmaniasis (ACL), with characteristics such as papules, verrucous and keloid lesions, and crusted and ulcerated plaques, distinct from those presented by common injuries (Baptista et al., 2009; Guimarães et al., 2009; Quaresma et al., 2018). In an area hyperendemic for L. braziliensis transmission in northeastern Brazil, ACL accounted for 1.9% of all tegumentary leishmaniasis cases (Guimarães et al., 2009). Possible causes associated with ACL are host immune status (pregnancy, co-morbidities, immunosuppression (Iftikhar et al., 2003; Omidian and Mapar, 2006), environmental factors, and strain of the parasite (Guimarães et al., 2016). However, the majority of such patients do not present with clinical co-morbidities or HIV infection and are not using immunosuppressive drugs (Da-Cruz et al., 1999). Furthermore, L. braziliensis is characterized by variable infectivity, virulence, and response to antileishmanial therapy (Rego et al., 2018; Patino et al., 2019a); thus, there is no consensus on the factors involved in cases of ACL, although these data seem to suggest that parasite factors may be more determinant.

In Brazil, ACL cases have been reported in the states of Rio de Janeiro (Baptista et al., 2009), Bahia (Guimarães et al., 2009), and Minas Gerais (Quaresma et al., 2018) and are associated with genetic variations of the parasite and lower response to treatment with antimonials. In the state of Minas Gerais (MG), ACL cases were observed in patients from the Xacriabá indigenous reserve located in the municipality of São João das Missões. The reserve is predominantly composed of Brazilian savannah (cerrado) vegetation, and Lutzomyia intermedia is the main vector of L. (V.) braziliensis in this region (Rego et al., 2018). In patients from Xacriabá, cytokine/chemokine expression in skin biopsies is associated with the time of lesions, but not with the type of injury. Additionally, histopathological analysis of cutaneous tissue samples did not show any differences between patients with different types of lesions (Costa-Silva et al., 2014). However, genetic polymorphisms are correlated with typical or atypical clinical manifestations (Quaresma et al., 2018). A large number of therapeutic failures were observed in patients with atypical lesions, and an in vitro study of antileishmanial drug susceptibility reported that strains from atypical manifestations are more resistant to Glucantime, the antileishmanial treatment recommended by the WHO (Rugani et al., 2019). Moreover, atypical manifestations have been demonstrated to be related to therapeutic failure (Guimaraes et al., 2016).

Proteomic analysis is a fundamental tool for understanding physiological processes and for studying the relationships between the genotype and the phenotype. Quantitative proteomics have been used for several Leishmania species in studies aiming at different aspects of biology, such as identifying protein modification during differentiation in L. donovani (Pawar et al., 2020), identification of differentially abundant proteins probably involved in the virulence of amastigote and promastigote forms of L. infantum (Fialho-Junior et al., 2021), and analysis of in vitro and in vivo models of cutaneous leishmaniasis using L. amazonensis and L. major (Negrão et al., 2019). Here, we performed a proteomic analysis using TMT labeling followed by mass spectrometry (MS) to identify differentially abundant proteins in L. braziliensis promastigotes that cause typical and atypical lesions. Our findings contribute to the characterization of the selected L. braziliensis strains, highlighting the importance of conducting new studies to elucidate the factors involved in the wide diversity of clinical manifestations and drug response outcomes in clinical practice.

2 MATERIALS AND METHODS

2.1 Ethics Statement
Leishmania field strains were obtained from human patients living in the Xacriabá indigenous community located in São João das Missões municipality, Minas Gerais, Brazil (Quaresma et al., 2018). Samples from other endemic areas were obtained from the outpatient care clinic at Centro de Referência em Leishmanioses – Instituto René Rachou-PIOCRUZ from 1993 to 1998. All patients involved in this study provided written informed consent, and experimental procedures were approved by the IRR Research Ethics Committee in Human Research, the National Committee for Research Ethics (Comissão Nacional de Ética em Pesquisa – CONEP; process 355/2008), and the National Indian Foundation (Fundação Nacional do Índio – FUNAI; n° 149/CGEP/08).

2.2 Parasites
The L. braziliensis strains from typical (LbTL) lesions were isolated from patients from Belo Horizonte, MG, Brazil, identified as MHOM/BR/95/RR051 and BH17 and from São João das Missões, MG, Brazil identified as MHOM/BR/08/426 and MHOM/BR/09/346. The strains from atypical lesions (LbAL) were isolated from São João das Missões, MG, Brazil, identified as MHOM/BR/08/316 and MHOM/BR/08/340. The clinical features of typical and atypical lesions from which the parasites were isolated and the isolation and confirmation of the species were
performed as described by Quaresma et al. (2018). In summary, the typical lesions were characterized like circular or oval ulcers with an erythematous, infiltrated, firm, reddish and granular base and a well-delimited, elevated border. Atypical lesions were defined by the presence of unusual cutaneous wounds.

The isolation procedures were accomplished added lesion fragments to tubes containing NNN medium (Novy and McNeal, 1903; Nicolle, 1908) enriched with liquid Schneider’s medium and incubated at 25 ± 1°C. The cultures were examined weekly and were considered positive when Leishmania promastigotes were observed. The species identification methods performed for characterizing the isolates used in this study was done by the Leishmania Isolation, Culture and Typing Service of the Leishmania Collection of the Oswaldo Cruz Institute (Coleção de Leishmanio do Instituto Oswaldo Cruz – CLIOC) according to the protocol described by Cupolillo et al. (1994). We also used hsp70-PCR-RFLP which amplified a 1300-bp fragment of the hsp70 gene and subsequently the restriction profiles were obtained from HaeIII digestion of the PCR products. In addition to these methods the sequencing of the 1,300 bp fragment of hsp70 were performed. The combination of identification methods allowed the characterization of parasites as L. braziliensis.

Promastigotes of L. braziliensis were maintained in M199 culture media (SigmaAldrich/Merck) supplemented with 10% fetal bovine serum (ThermoFischer/Gibco), 100 units/mL penicillin (ThermoFischer/Gibco), 100 µg/mL streptomycin (ThermoFischer/Gibco), 12.5 mM glutamine (ThermoFischer/Gibco), 0.1 M adenine (SigmaAldrich/Merck), 205 µg/mL hemin, and 40 mM HEPES (SigmaAldrich/Merck), pH 7.4 at 26°C. Overall, six isolates were evaluated: four from typical lesions and two from atypical lesions. All strains were maintained in M199 medium and incubated at 25 ± 1°C. The cultures were examined weekly and were considered positive when Leishmania promastigotes were observed.

Equal amounts of protein (300 µg) from each sample were reduced via incubation with 50 mM dithiothreitol (DTT) for 1 h at 24°C and subsequently alkyated with 150 mM iodoacetamide (IAA) for 30 min at room temperature in the dark. Before the digestion step, the samples were washed with buffer (6M urea and 50 mM TEAB) to dilute the CHAPS present in the lysis buffer. Protein purification and concentration filters (Micon ® Ultra-0.5 mL) were used for these washes. Enzymatic digestion was performed using trypsin (Promega, Madison) at a ratio of 1:50 for 16 h at 37°C.

After protein digestion, peptides were labeled with specific isobars from the TMT® 10plex Isobaric Mass Tagging Kit (Thermo Fisher Scientific/Pierce Biotechnology, Rockford, USA) following the manufacturer’s instructions. Briefly, 15 µg of each sample was labelled with 0.266 mg of an isobaric amine-reactive tag (TMT10-126, TMT10-127N, TMT10-127C, TMT10-128N, TMT10-128C, and TMT10-129N). The reaction mixture was incubated for one hour at room temperature for complete labeling. The reaction was quenched by the addition of 5% hydroxyamine, and labelled peptides were combined at a ratio of 1:1:1:1:1:1. The samples were dried using a SpeedVac and stored for further analysis. The preparation process was performed in biological triplicates.

2.3.2 High pH Reversed Phase Pre-Fractionation
Labeled peptide mixtures were dissolved in buffer A (20 mM ammonium formate, pH 9.3) and fractioned using an Acquity UPLC M-Class Peptide CSH C18 column (1.7 µm, 300 µm x 100 mm) (Waters) on an UltiMate 3000 high-pressure liquid chromatography (HPLC) system (Dionex, Sunnyvale, CA, USA) operating at 5 µL/min. Each set was eluted using the following chromatographic gradient expressed as a percentage of solvent B (20% solution A/80%ACN): 2–40% for 27 min, 40–50% in 4 min, 50–70% in 4 min, and 70–95% in 5 min. Each sample was separated into 15 fractions that were further merged into five concatenated fractions, and dried using a SpeedVac prior to MS analysis.

2.3.3 LC-MS/MS
Pre-fractionated TMT-labeled peptides were resuspended in solvent A (0.1% (v/v) formic acid) and subsequently injected into an EASY-nLC system (Thermo) with a two-column system setup. The pre-column was 3 cm in length and 100 µm in inner diameter, and it was packed with 5 µm (particle size) Reprosil-Pur C18-AQ resin (Dr. Maisch GmbH). An analytical column (17 cm × 75 µm) was packed with a 3 µm Reprosil-Pur C18-AQ resin (Dr. Maisch GmbH). Peptides from each fraction were eluted for 68 min using the following gradient expressed as a percentage of solution B (95% acetonitrile/0.1% formic acid): 2–5% in 1 min, 5–25% in 50 min, 25–40% in 10 min, 40–95% in 1 min, 95% in 5 min and 95–2% in 1 min, at a constant flow of 300 nL/min. The Q Exactive HF-X hybrid quadrupole-Orbitrap mass spectrometer (Thermo) was operated in positive mode using data-dependent acquisition (DDA) (Top 20). Peptide ions were resolved in the Orbitrap (MS), in the range of 350 to 1500 m/z with a resolution of 120,000 FWHM (AGC target 3e6 or
maximum injection time of 50 ms). At each MS, the 20 most intense ions (Top 20), with the minimum AGC target 1e3, were selected in the quadrupole, using an isolation window equal to 0.7 m/z. These ions were selected for fragmentation (MS2) by higher-energy collision dissociation (HCD), with a normalized collision energy of 33%. The originating fragments were resolved in Orbitrap with a resolution of 45,000 FWHM (AGC target 1e5 or maximum injection time of 60 ms) and included in a dynamic exclusion list for 30 s.

2.3.4 Data Analysis

Raw data were analyzed using the Proteome Discoverer 2.1 software. The database search was performed by the SEQUEST using the Leishmania braziliensis NCBI database (25,611 sequences). Database search parameters included: i) maximum of two trypsin missing cleavages, ii) carbamidomethylation of cysteine as a fixed modification, iii) oxidation of methionine, N-terminal acetylation of protein, and TMT 6plex (lysine and N-terminal peptide) as variable modifications, iv) precursor and fragment mass tolerance of 10 ppm and 0.02 Da, respectively; v) 1% false discovery rate (FDR); and vi) unique peptides plus razor ions were grouped into the respective proteins. Only master proteins with a 1% FDR were considered for the analysis.

Before statistical analyses, we normalized the log2 transformed ion reporter abundance using the “control” sample (pool of all analyzed samples) for all three datasets. Subsequently, data were normalized by subtracting the median of each group using the Perseus program (https://maxquant.net/perseus). After combining the three sets, we subtracted the average over all conditions (biological/technical) for each protein. Proteins significantly regulated between LbAL and LbTL conditions were determined by the one-way ANOVA statistical test ($P < 0.05$) plus log2 fold change of 0.584, using DanteR software (Polpitiya et al., 2008).

The differentially abundant proteins were functionally categorized through annotations of biological processes (BP) and molecular functions (MF) cataloged according to the Gene Ontology (GO) consortium. This set of genomic data was analyzed using the bioinformatics platform TriTrypDB release 40 (http://tritrypdb.org/tritrypdb/). For each category, Fischer’s exact test was used to test the enrichment of selected proteins against all proteins identified in the study. A false discovery rate (FDR) and an adjusted $P < 0.05$ were set as thresholds to define the significance of the functional enrichment.

To evaluate the potential relationship among these proteins using enriched GO categories, we predicted the protein-protein interaction networks associated with the whole proteome of the organism. For this prediction analysis, we used the STRING 10.5 database with a cut-off value of 0.4 considered to be of medium confidence. This database provides a network of predicted interactions or interactions already described in the literature between proteins or between genes (protein-protein interaction networks, http://string-db.org). Finally, the KEGG (Kyoto Encyclopedia of Genes and Genomes) database was used via the metabolic pathways enrichment tool (TriTrypDB bioinformatics platform) to analyze the pathways of the identified differentially abundant proteins and to understand their biological significance.

2.3.5 Data Availability Statement

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD029995.

2.4 Validation Proteomic Data

2.4.1 Peroxidase Activity

Peroxidase activity was measured using $10^8$ promastigotes from each strain in the LbTL and LbAT groups. Promastigotes were lysed by gentle shaking in 50 µL of 0.1% Triton X-100 for 30 min at room temperature. Next, 50 µM H2O2 (final concentration) was added, followed by incubation at 37°C for 30 min. The reaction was stopped by adding 0.75 mL of trichloroacetic acid solution (8% w/v), and the precipitate was removed by centrifugation. To the supernatant, 0.2 mL of 10 mM ferrous ammonium sulphate and 0.1 mL of 2.5 M potassium thiocyanate were added, and the remaining amount of H2O2 was determined spectrophotometrically (480 nm) by calibration against a standard curve with known concentrations of H2O2 (Jiang et al., 2005).

Statistical analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA, USA). Data are presented as means of the group. Comparisons between different groups were made using one-way ANOVA followed by Bonferroni’s test, and statistical significance was set at $P < 0.05$.

3 RESULTS

3.1 Identification and Relative Abundance of Proteins From Atypical and Typical Strains

We performed an isobaric tagging and high-resolution mass spectrometry strategy to compare the proteome of L. braziliensis strains that cause atypical lesions (LbAL, n=2) and L. braziliensis strains that cause typical lesions (LbTL, n=4). Each strain was analyzed in triplicate, resulting in triplicates of independent experiments. This approach enabled the identification of 4,048 non-redundant proteins (Supplementary Table S1), of which 2,229 proteins were present in all three independent runs (Figure 1A). To assess the differentially abundant proteins, we compared the relative abundance values of the identified proteins in LbAL versus LbTL strains. Our results showed that the abundance of 298 and 234 proteins significantly increased and decreased in LbAL strains, respectively, compared to LbTL strains (Figures 1B). However, when we considered only proteins identified in at least two of the three runs, 254 (Supplementary Table S2) and 196 (Supplementary Table S3) proteins were upregulated and downregulated at LbAL versus LbTL (Figures 1C, D).
3.2 Functional Analysis

Gene Ontology (GO) data were used to glean insights into the differences between atypical and typical \textit{L. braziliensis} strains. The GO enrichment of regulated proteins associated GO term to 37 proteins with increased abundance and 16 with decreased abundance in atypical strains compared to typical strains. These proteins were categorized into functional groups (Figure 2).

Regarding Molecular Function (MF), the category Oxidoreductase activity, acting on a sulfur group of donors ($P=4.11\times10^{-4}$) followed by enzyme inhibitor activity ($P=3.33\times10^{-4}$) were significantly enriched in the group of upregulated proteins. These groups are represented mainly by the following proteins: trypanothione reductase, peptide methionine sulfoxide reductase-like, and ecotin. In the group of downregulated proteins, we observed that oxidoreductase activity, acting on CH-OH group of donors (6.27e-4), protein serine/threonine kinase activity ($P=6.45\times10^{-4}$), oxidoreductase activity ($P=7.30\times10^{-4}$), and oxidoreductase activity, acting on a sulfur group of donors, disulfide as acceptor ($P=1.03\times10^{-3}$) were among the significant categories. These groups are represented mainly by the following proteins: malate dehydrogenase and choline dehydrogenase (Figure 2A and Table 1).

The biological process (BP) with statistical significance among proteins with increased abundance in atypical strains compared to typical strains were cellular nitrogen compound biosynthetic process ($P=4.68\times10^{-5}$ with 27 proteins), peptide metabolic process ($P=1.49\times10^{-4}$ with 20 proteins), and cellular amide metabolic process ($P=2.42\times10^{-4}$ with 20 proteins). These groups are mainly represented by ribosomal proteins. In contrast, no significantly enriched category was found for downregulated proteins (Figure 2B and Table 2).

3.3 Prediction of Protein-Protein Interaction (PPI)

To identify possible interactions between the identified proteins, a prediction analysis of protein interactions was performed using String 10.5. The network obtained was composed of 21 upregulated and 9 downregulated proteins. The obtained networks were later edited in Cytoscape 3.4.0, to assign colors to positive and negative adjustment values. The positively
regulated proteins interacted with each other, mainly represented by reductase proteins, and similarly, the negatively regulated proteins interacted with each other, mainly represented by dehydrogenases proteins. Moreover, it is possible to observe the interactions among ribosomal proteins, all of which are positively regulated in strains isolated from atypical lesions compared to strains isolated from typical lesions (Figure 3).

3.4 Analysis of Enrichment of Metabolic Pathways

The KEGG tool was used to identify the most relevant pathways associated with regulated proteins in the promastigote forms of Leishmania, causing atypical lesions. Regarding positively regulated proteins, the analysis showed the enrichment of five pathways: cysteine and methionine metabolism ($P=1.58\times10^{-4}$, with 10 proteins), glutathione metabolism ($P=5.96\times10^{-3}$, with 6 proteins), phenylalanine metabolism ($P=6.79\times10^{-3}$, with 6 proteins), polyketide sugar unit biosynthesis ($P=8.46\times10^{-3}$, with 6 proteins), and tyrosine metabolism ($P=9.85\times10^{-3}$, with 9 proteins). In contrast, negatively regulated proteins participated in six pathways: carbon fixation pathways in prokaryotes ($P=1.37\times10^{-4}$, with 8 proteins); valine, leucine, and isoleucine degradation ($P=4.60\times10^{-3}$, with 5 proteins); benzoate degradation ($P=7.99\times10^{-3}$, with 5 proteins); glyoxylate and dicarboxylate metabolism ($P=8.69\times10^{-3}$, with 5 proteins); geraniol degradation ($P=9.85\times10^{-3}$, with 3 proteins); and one carbon pool by folate ($P=9.85\times10^{-3}$, with 3 proteins) (Figure 4). Proteins belonging to each pathway are listed in Table 3, where it can be observed that each protein participates in more than one pathway, except in the case of glutathione metabolism. To verify the interactions between the identified proteins belonging to the enriched pathways, prediction analysis of protein interactions was performed (Figure 5), highlighting that the dehydrogenases were negatively regulated and interacted with each other, and trypanothione and tryparedoxin were positively regulated and interacted with each other.

3.5 Peroxidase Activity

Glutathione (GSH) plays a central role in cell defense against oxidative stress. In trypanosomatides, the removal of peroxides is performed by tryparedoxin peroxidase (Collotti et al., 2013). Tryparedoxin peroxidase was found among the upregulated proteins belonging to the glutathione pathway (ratio LbAL vs LbTL = 0.993897). Therefore, the antioxidant capacities of different strains were evaluated. Since after 30 min of exposure to 50 µM hydrogen peroxide, protein extracts from strains belonging to the atypical group consumed all H$_2$O$_2$, the reported value should be interpreted as lower boundary (no standard deviation can be calculated), while those in the typical group consumed an average of 15.7 µM of H$_2$O$_2$. The hydrogen peroxide consumption in the atypical group was 3.01-fold higher than that in the typical group ($P<0.001$; Figure 6).

4 DISCUSSION

Determining factors of atypical cutaneous leishmaniasis (ACL) caused frequently by Leishmania (Viannia) braziliensis remain unclear. It is possible that these clinical forms are determined by host and parasite factors, as demonstrated for other clinical forms of leishmaniasis. However, histopathological analysis of cutaneous tissue samples and cytokine/chemokine expression in skin biopsies from ACL patients showed no association with the
In contrast, the parasite presented genetic polymorphism correlated with atypical clinical manifestations (Quaresma et al., 2018) and was more resistant to N-methylglucamine antimonate (Rugani et al., 2018); clinical cases have been associated with therapeutic failures (Guimarães et al., 2016). Thus, we performed a comparative proteomic analysis to identify differentially abundant proteins among L. (V.) braziliensis strains isolated from atypical lesions (LbAL) compared to isolates from typical lesions (LbTL). The strains used in the present study were previously characterized for genetic polymorphism, as well as for resistance to N-methylglucamine antimonate (Rugani et al., 2018; Quaresma et al., 2018).

Since the role of the parasite in a large clinical plasticity of L. braziliensis infections is not clear this study aims to contribute to the knowledge about the factors involved in such pleomorphism. We quantified 4,048 proteins, of which 254 and 196 proteins showed increased and decreased abundance, respectively, in atypical strains compared to typical strains. To identify potential factors related to each strain, proteins were categorized into functional groups based on molecular function (MF) and biological process (BP), followed by prediction analysis of protein interactions (PPI) as well as pathway enrichment analysis using the KEGG tool. The data pointed to upregulated redox activity in atypical strain, among others, the peroxidase activity test validated the findings.

### Table 1: Gene Ontology (GO) enrichment analysis of Molecular Function in differentially regulated proteins in L. braziliensis from atypical lesion (LbAL) compared to L. braziliensis from typical lesion (LbTL).

| TERM | Fold change (P value) | PROTEINS | RATIO (LbAL vs LbTL) |
|------|-----------------------|----------|---------------------|
| Upregulated proteins | | | |
| Oxidoreductase activity, acting on a sulfur group of donors | 7.43 (4.11e-4) | trypanothione reductase | 2.417 |
| | | peptide_methionine sulfoxide reductase-like | 1.060 |
| | | putative thioredoxin | 0.984 |
| | | thiol-dependent_reductase_1 | 0.709 |
| | | putative glutaredoxin-like protein | 0.649 |
| Enzyme inhibitor activity | 18.26 (3.33e-4) | ecotin | 1.917 |
| Downregulated proteins | | | |
| Oxidoreductase activity, acting on CH-OH group of donors | 7.02 (6.27e-4) | mitochondrial malate dehydrogenase | -1.150 |
| | | choline dehydrogenase like protein | -1.062 |
| | | glycosomal malate dehydrogenase | -0.944 |
| | | dehydrogenase-like protein | -0.888 |
| | | putative short chain 3-hydroxacyl-CoA dehydrogenase | -0.825 |
| Protein serine/threonine kinase activity | 9.70 (6.45e-4) | putative target of rapamycin (TOR) kinase 1 | -1.744 |
| | | protein kinase A catalytic subunit isomorph 1 | -0.765 |
| | | protein kinase A catalytic subunit | -0.676 |
| Oxidoreductase activity | 2.73 (7.30e-4) | mitochondrial malate dehydrogenase | -1.150 |
| | | choline dehydrogenase, like protein | -1.062 |
| | | putative short chain dehydrogenase | -1.017 |
| | | conserved hypothetical protein (134065654) | -0.978 |
| | | glycosomal malate dehydrogenase | -0.944 |
| | | putative endoplasmic reticulum oxidoreductin | -0.938 |
| | | dehydrogenase-like protein | -0.888 |
| | | putative short chain 3-hydroxacyl-CoA dehydrogenase | -0.825 |
| | | fatty acid desaturase | -0.700 |
| | | aldehyde dehydrogenase, mitochondrial precursor | -0.696 |
| | | conserved hypothetical protein (134063632) | -0.662 |
| | | putative C-1-tetrahydrofolate synthase, cytoplasmic | -0.655 |
| | | putative endoplasmic reticulum oxidoreductin | -0.938 |
| | | conserved hypothetical protein (134063632) | -0.662 |

Proteins sorted by log2-ratio.
Inside the mammalian host, *Leishmania* lives in the lethal enzymatic environment of macrophage cells, where they deal with the macrophage-generated oxidative stress to survive. Their survival is attributed to a unique redox metabolism with which the parasite has evolved. In the present study, the oxidoreductase activity of proteins that act on sulfur group donors was upregulated in atypical strains compared to typical strains. Our results show that in this process, five proteins were increased, represented mainly by trypanothione reductase (TR), with a higher positive ratio (2.42) followed by peptide methionine sulfoxide reductase-like (Msr) (ratio =1.06). Both TR and Msr are proteins that catalyze reduction reactions and contribute to the antioxidant defenses of these parasites. TR is an enzyme found in trypanosomatides, equivalent to glutathione reductase. This enzyme is a homodimer NADPH-dependent flavoprotein oxidoreductase that participates in central thiol–disulfide exchange reactions as an electron donor in different metabolic pathways, from the synthesis of DNA precursors to oxidant

| TERM | Fold change (P value) | PROTEINS | RATIO (LbAL vs LbTL) |
|------|-----------------------|----------|---------------------|
| Upregulated proteins | 2.22 (4.68e-5) | putative 60S ribosomal protein L10a | 1.807 |
| Cellular nitrogen compound biosynthetic process | 40S ribosomal protein S24e | 1.988 |
| | 60S ribosomal protein L32 | 1.357 |
| | putative DNA-directed RNA polymerase II | 1.342 |
| | putative DNA primase large subunit | 1.287 |
| | FtsL-like methyltransferase | 1.237 |
| | nucleoside diphosphate kinase b | 1.224 |
| | putative 60S acidic ribosomal protein | 1.048 |
| | putative 40S ribosomal protein S30 | 1.041 |
| | deoxyribose-phosphate aldolase | 0.969 |
| | conserved hypothetical protein | 0.954 |
| | kynureninase | 0.952 |
| | conserved hypothetical protein | 0.891 |
| | 60S_acidic_ribosomal_protein_P2 | 0.816 |
| | inosine-guanosine transporter | 0.770 |
| | acidic ribosomal P2 beta protein | 0.769 |
| | putative methylthioadenosine phosphorylase | 0.717 |
| | putative 60S ribosomal protein L13a | 0.712 |
| | putative 60S ribosomal protein L19 | 0.708 |
| | putative arginyl-tRNA synthetase | 0.669 |
| | putative ribosomal protein S7 | 0.624 |
| | putative asparaginyl-tRNA synthetase | 0.624 |
| | putative ribosomal protein S35a | 0.616 |
| | putative ribosomal protein L27 | 0.609 |
| | putative ribosomal protein L15 | 0.601 |
| | putative 60S ribosomal protein L5 | 0.601 |
| | putative 60S ribosomal protein L110a | 1.807 |
| Peptide metabolic process and | 2.47 (1.49e-4) | putative 60S ribosomal protein L10a | 1.807 |
| Cellular amide metabolic process | 40S ribosomal protein S24e | 1.398 |
| | 60S ribosomal protein L32 | 1.357 |
| | FtsL-like methyltransferase | 1.287 |
| | conserved hypothetical protein | 1.119 |
| | putative 60S acidic ribosomal protein | 1.048 |
| | putative 40S ribosomal protein S30 | 1.041 |
| | conserved hypothetical protein | 0.891 |
| | 60S_acidic_ribosomal_protein_P2 | 0.816 |
| | acidic ribosomal P2 beta protein | 0.769 |
| | putative 60S ribosomal protein L13a | 0.712 |
| | thiol-dependent reductase_1 | 0.709 |
| | putative 60S ribosomal protein L19 | 0.708 |
| | putative arginyl-tRNA synthetase | 0.669 |
| | putative ribosomal protein S7 | 0.624 |
| | putative asparaginyl-tRNA synthetase | 0.623 |
| | putative ribosomal protein S35a | 0.616 |
| | putative ribosomal protein L27 | 0.609 |
| | putative ribosomal protein L15 | 0.601 |
| | putative 60S ribosomal protein L5 | 0.601 |
detoxification (Mittal et al., 2005; Colotti et al., 2013). TR neutralizes hydrogen peroxide produced by macrophages during infection through the tryparedoxin/tryparedoxin peroxidase I (TXN/TXNPx) system (Colotti et al., 2013). Therefore, TR inhibition increases the intracellular levels of reactive oxygen species that are lethal to the parasite. Similarly, Msr is a protein that catalyzes the reduction reaction, in this case, reducing oxidized methionine residues. Rodriguez-Veja et al. (2021) showed that strains of L. braziliensis related to disseminated leishmaniasis (DL) might also have a greater resistance to oxidative stress, mediated by the increased abundance of trypanothione reductase, and thioredoxin-like fold domain containing protein. Consistently, disruption of the trypanothione reductase gene decreases the Leishmania infectivity and its ability to survive within the macrophage. Thus, our results indicate that the parasites that cause atypical lesions present increased abundance of some proteins related to redox homeostasis, which may confer greater survival inside macrophages.

Pentavalent antimony-containing compounds (sodium stibogluconate Pentostam® and N-methyl-glucamine Glucantime®) have been the first-line drugs for the treatment of all clinical forms of leishmaniasis since 1940 (Davidson, 1999), and as no human vaccine is in clinical use, chemotherapy relying on pentavalent antimonial still is the most important control for leishmaniasis. The mechanism of action of antimony has not been fully elucidated; however, SbIII (stibogluconate) is purported to generate disturbances in the thiol redox potential of the parasite by inducing the efflux of intracellular thiols and by inhibiting trypanothione reductase, resulting in cell death by oxidative stress (Wyllie et al., 2004). The antimony susceptibility test (EC 50 assay) revealed that L. braziliensis lines

**FIGURE 3** Prediction of interaction among differentially abundant proteins in L. braziliensis that are part of enriched GO categories. Red and green represents upregulated and downregulated proteins in LbAL vs LbTL comparison.
overexpressing cytosolic tryptaredoxin peroxidase (cTXNPx) had a 2-fold increase in resistance to SbIII compared to the untransfected parental line. Furthermore, these clones were more tolerant to exogenous H$_2$O$_2$ than the untransfected parental line (Moreira and Murta, 2016). Similarly, overexpression of nucleoside diphosphate kinase b and elongation factor 2 results in an increase in SbIII resistance in *L. braziliensis* (Andrade and Murta, 2014). Corroborating these literature data, the results of the present work, in which we used naturally-occurring antimony-resistant strains that cause AL, showed that these strains present upregulated reductase proteins (trypanothione reductase, thioredoxin, peptide methionine sulfoxide reductase-like, thiol-dependent reductase 1, nucleoside diphosphate kinase b, deoxyribose phosphate aldolase, and methylthioadenosine phosphorilase, which interact with each other (Figure 3). Some of these proteins also participate in glutathione metabolism (one of the enrichment pathways shown by the KEGG tool). Atypical strains showed 3.01-fold higher peroxidase activity than typical ones (*P*<0.001, Figure 5). As already mentioned, the atypical strains used in present study were previously characterized as resistant to N-methylglucamine antimonate (Rugani et al., 2018) then, we believe that, collectively, it was possible to identify the proteins related to antimony resistance and prove the greater peroxidase activity in strains of the typical group. These data shed new light on ACL cases that have been associated with therapeutic failures.

Therefore, regarding MF, we observed enrichment of “Enzyme inhibitor activity” as upregulated terms in atypical strains, including the proteins ecotin, ecotin-like, and protein phosphatase inhibitor 2 (IPP-2). Ecotin is a serine protease inhibitor produced by hundreds of microbial species, including pathogens such as *Leishmania* spp. Parasites encode inhibitors of serine protease (ISP), which inhibits serine proteases of the immune response system and manipulates the host physiological processes to ensure their survival. In *L. major*, ISP targets host serine peptidases and influences the early stages of infection of the mammalian host (Eschenlauer et al., 2009). Alam et al. (2016) identified, purified, and characterized an endogenous ISP from an Indian strain of *L. donovani*, which causes fatal visceral leishmaniasis, and these inhibitors show varying and entirely contrasting efficacies toward serine proteases of its own as well as of higher organisms. To that authors, this indicates that it accelerates disease progression and drives parasite survival by inhibiting the activities of host serine proteases. Subsequently, it was demonstrated that ecotin blocks activation of the complement lectin pathway by inhibiting its key activator enzymes, MASP-1 and MASP-2. Furthermore, by inhibiting MASP-3, ecotin also disrupts the fundamental link between lectin and alternative pathways. Thus, ecotin is a potent, versatile self-defense tool that blocks multiple antimicrobial activities in the serum. These findings suggest that ecotin may be a relevant antimicrobial drug target (Nagy et al., 2019). Thus, our data suggest that ecotin could be a new drug target to be tested in strains that are resistant to antimony, as already mentioned. Our data also showed positive regulation of protein phosphatase inhibitor 2 (IPP-2). Protein phosphorylation and dephosphorylation are well recognized as important processes that regulate multiple physiological mechanisms. To date, there are no reports on IPP-2 from *Leishmania*; nevertheless, it is a protein involved in the regulation of phosphoproteins and regulation of signal transduction that is able to impede the activity of a protein phosphatases, enzymes that hydrolyzes phosphate groups from phosphorylated proteins. Upregulation of phosphatase inhibitors consequently allows higher activity of...
### TABLE 3 | KEGG enriched pathways of differentially regulated proteins in *L. braziliensis* from atypical lesion (LbAL) compared to *L. braziliensis* from typical lesion (LbTL).

| PATHWAY                                      | PROTEINS                                                                 | RATIO (LbAL vs LbTL)  |
|----------------------------------------------|--------------------------------------------------------------------------|-----------------------|
| **UPREGULATED**                              |                                                                          |                       |
| Cysteine and methionine metabolism           | putative thymine-7-hydroxylase                                           | 1.456151              |
|                                              | FtsJ-like_methyltransferase                                              | 1.287025              |
|                                              | putative sterol 24-c-methyltransferase                                   | 0.814614              |
|                                              | putative methylthioadenosine phosphorylase                              | 0.71708               |
|                                              | conserved hypothetical protein (130463540)                               | 0.686384              |
|                                              | putative aspartate aminotransferase                                     | 0.679376              |
|                                              | putative branched-chain amino acid aminotransfer                         | 0.639421              |
|                                              | tyrosine aminotransfer                                                  | 0.62752               |
|                                              | putative arginine N-methyltransferase, type III                         | 0.616916              |
|                                              | putative malate dehydrogenase                                           | 0.58559               |
| Glutathione metabolism                       | trypanothione reductase                                                 | 2.417349              |
|                                              | hypothetical protein, unknown function (322504762)                      | 1.724753              |
|                                              | trypaedoxin_peroxidase                                                  | 0.993897              |
|                                              | thiol-dependent_reductase_1                                             | 0.708709              |
|                                              | putative trypanothione synthetase                                       | 0.689969              |
|                                              | putative glutaredoxin-like protein                                      | 0.649122              |
| Phenyalanine metabolism                      | FtsJ-like_methyltransferase                                             | 1.287025              |
|                                              | putative sterol 24-c-methyltransferase                                   | 0.81461               |
|                                              | conserved hypothetical protein (130463540)                               | 0.686384              |
|                                              | putative aspartate aminotransfer                                        | 0.679376              |
|                                              | tyrosine aminotransfer                                                  | 0.62752               |
|                                              | conserved hypothetical protein (130463845)                               | 0.598311              |
| Polyketide sugar unit biosynthesis           | FtsJ-like_methyltransferase                                             | 1.28703               |
|                                              | putative sterol 24-c-methyltransferase                                   | 0.81461               |
|                                              | conserved hypothetical protein (190463540)                               | 0.68638               |
|                                              | tyrosine aminotransfer                                                  | 0.62752               |
|                                              | putative arginine N-methyltransferase, type III                         | 0.61692               |
|                                              | putative lanosterol synthase                                            | 0.61456               |
| Tyrosine metabolism                          | FtsJ-like_methyltransferase                                             | 1.28703               |
|                                              | putative sterol 24-c-methyltransferase                                   | 0.81461               |
|                                              | Acyltransferase                                                         | 0.81126               |
|                                              | putative NADP-dependent alcohol dehydrogenase                           | 0.69938               |
|                                              | conserved hypothetical protein (130463540)                               | 0.68638               |
|                                              | putative aspartate aminotransfer                                        | 0.679376              |
|                                              | tyrosine aminotransfer                                                  | 0.62752               |
|                                              | putative arginine N-methyltransferase, type III                         | 0.61692               |
|                                              | putative lanosterol synthase                                            | 0.61456               |
| **DOWNREGULATED PROTEINS**                   |                                                                          |                       |
| Carbon fixation pathways in prokaryotes       | mitochondrial malate dehydrogenase                                      | -1.1499               |
|                                              | glycosomal malate dehydrogenase                                         | -0.94403              |
|                                              | putative short chain 3-hydroxacyl-CoA dehydrogenase                     | -0.82537              |
|                                              | formate—tetrahydrofolate ligase                                         | -0.81918              |
|                                              | methylcrotonoyl-coa carboxylase biotinylated subunit protein-like protein| -0.68285              |
|                                              | putative C-1-tetrahydrofolate synthase, cytoplasmic                      | -0.85468              |
|                                              | enoyl-CoA hydratase/isomerase family protein, conserved                  | -0.62284              |
|                                              | mitochondrial DNA topoisomerase II                                      | -0.60924              |
| Valine, leucine and isoleucine degradation    | putative short chain 3-hydroxacyl-CoA dehydrogenase                     | -0.82537              |
|                                              | aldehyde dehydrogenase, mitochondrial precursor                         | -0.69571              |
|                                              | methylcrotonoyl-coa carboxylase biotinylated subunit protein-like protein| -0.68285              |
|                                              | enoyl-CoA hydratase/isomerase family protein, conserved                  | -0.62284              |
|                                              | mitochondrial DNA topoisomerase II                                      | -0.60924              |
| Benzoate degradation                         | putative short chain 3-hydroxacyl-CoA dehydrogenase                    | -0.82537              |
|                                              | aldehyde dehydrogenase, mitochondrial precursor                         | -0.69571              |
|                                              | methylcrotonoyl-coa carboxylase biotinylated subunit protein-like protein| -0.68285              |
|                                              | enoyl-CoA hydratase/isomerase family protein, conserved                  | -0.62284              |
|                                              | mitochondrial DNA topoisomerase II                                      | -0.60924              |
| Glyoxylate and dicarboxylate metabolism      | mitochondrial malate dehydrogenase                                      | -1.1499               |
|                                              | glycosomal malate dehydrogenase                                         | -0.94403              |
|                                              | methylcrotonoyl-coa carboxylase biotinylated subunit protein-like protein| -0.68285              |
|                                              | enoyl-CoA hydratase/isomerase family protein, conserved                  | -0.62284              |
|                                              | mitochondrial DNA topoisomerase II                                      | -0.60924              |
| Geraniol degradation                         | putative short chain 3-hydroxacyl-CoA dehydrogenase                    | -0.82537              |

(Continued)
phosphorylated proteins, which are associated with diverse cellular functions, including glycolysis, motility, mitosis, apoptosis, cell cycle progression, and signal transduction (Qureshi et al., 2019).

A clustering of several ribosomal proteins interacting with each other was observed with BP enrichment of 12 (from 27) ribosomal proteins, of which 9 interact with each other and all of which are positively regulated in strains from atypical lesions. Eukaryotic ribosomes have approximately 70 proteins, 30 of which are present in the smaller sub-unit and 40 in the larger sub-unit (Tsurugi et al., 1978), therefore, suggesting that 12 regulated proteins may not be related to increased ribosomal activity; however, in Leishmania spp., ribosome-related proteins have been considered relevant molecules during infection and have been shown to modulate cellular activity and cytokine release (Cordeiro-Da-Silva et al., 2001). Therefore, they are good candidates for vaccination (Iborra et al., 2008; Brito et al., 2017). These ribosomal proteins could be associated with immune response modulation, favorable to the parasites from atypical strains which the disease duration was significantly longer among ACL individual as reported in Guimarães et al. (2016).

Our results also demonstrate negative regulation of the oxidoreductase activity, acting on CH-OH group of donors, as well as acting on a sulfur group of donors, disulfide as an acceptor, groups represented mainly by malate dehydrogenase and choline dehydrogenase in atypical strains compared to typical strains. In this case, the higher negative ratios were malate dehydrogenase (-1.15) and choline dehydrogenase (-1.06). Furthermore, these categories included several downregulated dehydrogenases (malate dehydrogenase, choline dehydrogenase, dehydrogenase-like protein, short chain 3-hydroxyacyl-CoA dehydrogenase, and aldehyde dehydrogenase) that interact with each other (Figure 3). Dehydrogenases are oxidoreductase enzymes that catalyze the transfer of hydrogen and a pair of electrons from a reduced substrate, which is oxidized in the reaction, to an electron-receiving molecule, which in turn, is reduced. In higher eukaryotes, mitochondrial MDH (mMDH) is involved in the

**TABLE 3** | Continued

| PATHWAY                              | PROTEINS                                                                 | RATIO (LbAL vs LbTL) |
|--------------------------------------|--------------------------------------------------------------------------|----------------------|
| One carbon pool by folate            | aldehyde dehydrogenase, mitochondrial precursor                         | -0.69571             |
|                                      | enoyl-CoA hydratase/isomerase family protein, conserved                  | -0.62284             |
|                                      | putative short chain 3-hydroxyacyl-CoA dehydrogenase                     | -0.82537             |
|                                      | aldehyde dehydrogenase, mitochondrial precursor                         | -0.69571             |
|                                      | enoyl-CoA hydratase/isomerase family protein, conserved                  | -0.62284             |

In bold proteins that are in more than one pathway, proteins sorted by log2-ratio.

**FIGURE 5** | Prediction of interaction among differentially abundant proteins in L. braziliensis that are part of enriched pathways. Red and green represents upregulated and downregulated proteins in LbAL vs LbTL comparison.
transfer of reducing equivalents from the cytosol to the mitochondria, which is essential for the activity of the glycolytic pathway in the cytosol. MDH has been demonstrated in *Leishmania* over 20 years ago (Mottram and Coombs, 1985), although the metabolic roles of MDH isozymes in trypanosomatides have not yet been clearly established. Leroux et al. (2006) demonstrated the presence of three MDH isoforms with slightly distinct biochemical properties and different subcellular localizations (mitochondrial and cytosolic) in *Leishmania* spp., and verified that these isozymes are remarkably more abundant in amastigotes than in promastigotes of *L. mexicana*. These authors presumed that the functional and biochemical features of these isozymes reflect the metabolic adaptation to the different nutrient sources that these parasites have to face during their life cycle. In *L. braziliensis*, MDH was inferred from homology; however, consistent with the present work, de Rezende et al. (2017) found MDH in *L. amazonensis*. Similarly, the presence of choline dehydrogenase in *Leishmania* spp. was inferred from homology. Thus, to date, no reports are available for experimental activity data involving malate dehydrogenase and choline dehydrogenase in *Leishmania* spp., and it is possible to speculate the role of these enzymes in relation to the strains studied in the present work.

Another negative regulation observed in atypical strains was related to serine/threonine kinase activity by the putative target proteins of rapamycin (TOR) and kinase 1 protein kinase. Initially, TORs were identified by mutations that confer resistance to a potent antifungal metabolite called rapamycin (Heitman et al., 1991). TOR kinases are key master regulators in eukaryotes, linking environmental conditions, such as nutrient availability and stimuli, to protein synthesis and cell cycle machinery in order to coordinate cell growth and replication. *Leishmania* TOR mutants were unable to survive or replicate in macrophages *in vitro* or to induce pathology or establish infections in mice *in vivo*. The loss of virulence is associated with a defect in acidocalcisome formation, a unique organelle of protozoans that plays an important role in energy metabolism (Madeira da Silva and Beverley, 2010). Based on these data, the downregulation of TOR in atypical strains could confer less virulence to this strain compared to typical strains; however, only one protein is not sufficient to determine virulence. Thus, we cannot infer the role of regulation of this protein in the strains studied. Similarly, the downregulation of kinase 1 protein alone is very difficult to speculate because it belongs to an important family of proteins. A number of studies have explored the role of individual *Leishmania* protein kinases in promastigote survival, metacyclic differentiation, and amastigote replication, as well as their role in infectivity. Baker et al. (2021) identified regulators of differentiation or survival in a systematic functional analysis of *Leishmania* protein kinases. They applied kinome-wide gene deletion and gene tagging in *L. mexicana* promastigotes to define protein kinases with life cycle transition roles. While 162 are dispensable, 44 protein kinase genes are refractory to deletion in promastigotes and are likely core genes required for parasite replication. Therefore, to understand the role of this molecular function and its downregulated proteins, further studies are needed on the strains used in the present work.

The results presented here show that promastigotes from *L. braziliensis* strains isolated from atypical and typical lesions have proteins with different abundances. The comparison between these strains enabled the reproducible identification of several proteins that distinguish the two groups. Strains isolated from atypical forms showed an upregulation of proteins which may confer greater survival inside macrophages, proteins that influence the early stages of infection of the mammalian host (ISP), and proteins associated with resistance to antimony therapy. Moreover, peroxidase activity was 3.01-fold higher in the atypical strains than in the typical strains.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ebi.ac.uk/pride/archive/, PXD029995.

**AUTHOR CONTRIBUTIONS**

BE: Data Curation, formal analysis, Investigation, Methodology, Visualization, Writing – Original Draft Preparation. MM-B: conceptualization, Methodology, Supervision, Writing – Review & Editing. VG: Methodology, Writing – Review & Editing TV-B: conceptualization, Methodology, Writing – Review & Editing ML: conceptualization, Methodology, Writing – Review & Editing. CG: conceptualization, Writing – Review & Editing. PQ: conceptualization, Methodology, Writing – Review & Editing. HA: conceptualization, funding acquisition, Methodology, Project.
administration, resources, Supervision, Writing – Review & Editing. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was supported by the Fundação de Amparo à Pesquisa do Estado de Minas Gerais [PPM00129-17], Instituto Nacional de Ciência e Tecnologia de Vacinas [CNPq-573547/2008-4/FAPEMIG/MS-CBB, APQ 00077-09] and Rede Mineira de Biomoléculas [CBBRED00012-14]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. HA is CNPq fellow (PQ). BE and MM-B are CAPES fellows. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**REFERENCES**

Alam, M. N., Das, P., De, T., and Chakraborti, T. (2016). Identification and Characterization of a Leishmania Donovani Serine Protease Inhibitor: Possible Role in Regulation of Host Serum Proteases. *Life Sci.* 144, 218–225. doi: 10.1016/j.lfs.2015.12.004
Andrade, J. M., and Murtu, S. M. (2014). Functional Analysis of Cytosolic Tryparedoxin Peroxidase in Antimony-Resistant and -Susceptible Leishmania braziliensis and Leishmania infantum Lines. *Parasit. Vectors* 7, 406. doi: 10.1186/1756-3305-7-406
Baker, N., Catta-Preta, C. M. C., Leal, C. A., Pires, M. Q., Oliveira, F. V., et al. (2021). Systematic Functional Analysis of Leishmania Protein Kinases Identifies Regulators of Differentiation or Survival. *Nat. Commun.* 12 (1), 1244. doi: 10.1038/s41467-021-21360-8
Baptista, C., Schubach, A. O., Madeira, M. F., Leal, C. A., Pires, M. Q., Oliveira, F. S., et al. (2009). Leishmania (Viannia) braziliensis Genotypes Identified in Lesions of Patients With Atypical or Typical Manifestations of Visceral Leishmaniasis: Evaluation by Two Molecular Markers. *Exp. Parasitol.* 121 (4), 317–322. doi: 10.1016/j.exppara.2008.12.006
Brito, R. C., Guimarães, F. G., Velloso, J. P., Corrêa-Oliveira, R. M., J., Reis, A. B., et al. (2017). Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies. *Int. J. Mol. Sci.* 18 (2), 371. doi: 10.3390/ijms18020371
Calvopina, M., Gomez, E. A., Uezato, H., Kato, H., Nonaka, S., and Hashiguchi, Y. (2005). Atypical Clinical Variants in New World Cutaneous Leishmaniasis: Disseminated, Erysipheoid, and Recidiva Cutis Due to Leishmania (V.) Panamensis. *Am. J. Trop. Med. Hyg.* 73 (2), 281–284. doi: 10.4269/ajtmh.2005.73.281
Colotti, G., Baiocco, P., Fiorillo, A., Bof, A., Reis, A., and Pimentel, H., Rui, J. C., Reis, A. B., et al. (2013). Structural Insights Into the Enzymes of the Trypanothione Pathway: Targets for Antileishmaniasis Drugs. *Future Med. Chem.* 5, 1861–1875. doi: 10.4155/fmc.13.146
Cordeiro-Da Silva, A., Borges, M., C., Guilvard, E., and Ouaisi, A. (2001). Dual Role of the Leishmania Major Ribosomal Protein S3a Homologue in Regulation of T- and B-Cell Activation. *Infect. Immun.* 69 (11), 6588–6596. doi: 10.1128/IAI.69.11.6588-6596.2001
Costa-Silva, M. F., Gomes, L. I., Martins-Filho, O. A., Rodrigues-Silva, R., de Moura Freire, J., Quaresma, P. F., et al. (2014). Gene Expression Profile of Cytokines and Chemokines in Skin Lesions From Brazilian Indians With Localized Cutaneous Leishmaniasis. *Mol. Immunol.* 57 (2), 74–85. doi: 10.1016/j.molimm.2013.08.008
Cupolloli, E., Grimaldi, G Jr, and Momen, H. (1994). A General Classification of New World Leishmania Using Numerical Zymotaxonomy. *Am. J. Trop. Med. Hyg.* 50 (3), 296–311. doi: 10.4269/ajtmh.1994.50.296

**ACKNOWLEDGMENTS**

We also would like to thank Editage (www.editage.com) for English language editing.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2022.824968/full#supplementary-material

**Supplementary Table S1** | All proteins identified by MS/MS.

**Supplementary Table S2** | Proteins identified by MS/MS in each run with abundance increased in Atypical (LbAL) strains compared to Typical (LbTL) strains.

**Supplementary Table S3** | Proteins identified by MS/MS in each run with abundance decreased in Atypical (LbAL) strains compared to Typical (LbTL) strains.

Da-Cruz, A. M., Filgueiras, D. V., Coutinho, Z., Mayrink, W., Grimaldi, G.jr., De Luca, P. M., et al. (1999). Atypical Mucocutaneous Leishmaniasis Caused by Leishmania braziliensis in an Acquired Immunodeficiency Syndrome Patient: T-Cell Responses and Remission of Lesions Associated With Antigen Immunotherapy. *Mem Inst Oswaldo Cruz* 94 (4), 537–542. doi: 10.1590/ S0071-07620000004000020

Davidson, R. N. (1999). Visceral Leishmaniasis in Clinical Practice. *J. Infect.* 39 (2), 112–116. doi: 10.1016/s0163-4453(99)00001-4

de Rezende, E., Kawahara, R., Peña, M. S., Palmisano, G., and Stolf, B. S. (2017). Quantitative Proteomic Analysis of Amastigotes From Leishmania (L.) amazonensis LV79 and PH8 Strains Reveals Molecular Traits Associated With the Virulence Phenotype. *PloS Negl. Trop. Dis.* 11 (11), e0006090. doi: 10.1371/journal.pntd.0006090

Eschenlauer, S. C., Faria, M. S., Morrison, L. S., Bland, N., Ribeiro-Gomes, F. L., DoxReis, G. A., et al. (2009). Influence of Parasite Encoded Inhibitors of Serine Peptidases in Early Infection of Macrophages With Leishmania Major. *Cell. Microbiol.* 11 (1), 106–120. doi: 10.1111/j.1462-5822.2008.01243.x

Fialho Junior, L., da Fonseca Pires, S., Burchmore, R., McGill, S., Weidt, S., Ruiz, J. C., et al. (2021). Proteomic Analysis Reveals Differentially Abundant Proteins Probably Involved in the Virulence of Amastigote and Promastigote Forms of Leishmania Infantum. *Parasit. Res.* 120, 679–692. doi: 10.1007/s00436-020-07020-8

Guimarães, L. H., Machado, P. R., Lago, E. L., Morgan, D. J., Schriefer, A., Bacellar, O., et al. (2009). Atypical Manifestations of Leishmaniasis in a Transmission Area of Leishmania braziliensis in the State of Bahia, Brazil. *Trans. R. Soc. Trop. Med. Hygiene* 103 (7), 712–715. doi: 10.1016/j.trstmh.2009.04.019

Guimarães, L. H., Queiroz, A., Silva, J. A., Silva, S. C., Magalhães, V., Lago, E. L., et al. (2016). Atypical Manifestations of Cutaneous Leishmaniasis in a Region Endemic for Leishmania braziliensis: Clinical, Immunological and Parasitological Aspects. *PloS Negl. Trop. Dis.* 10 (12), e0005100. doi: 10.1371/journal.pntd.0005100

Heitman, J., Movva, N. R., and Hall, M. N. (1991). Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast. *Sci.* 253 (5022), 905–909. doi: 10.1126/science.1715094

Ibora, S., Parody, N., Abánades, D. R., Bonay, P., Prates, D., Novais, F. O., et al. (2008). Vaccination With the Leishmania Major Ribosomal Proteins Plus CpG Oligodeoxynucleotides Induces Protection Against Experimental Cutaneous Leishmaniasis in Mice. *Microbes Infect.* 10 (19–11), 1133–1141. doi: 10.1016/j.micinf.2008.06.002

Ifitikhar, N., Bari, I., and Ejaz, A. (2003). Rare Variants of Cutaneous Leishmaniasis: Whitlow, Paronychia, and Sporotrichoid. *Int. J. Dermatol.* 42 (10), 807–809. doi: 10.1046/j.1365-4632.2003.02015.x

Jiang, Q., Yan, Y., Hu, G., and Zhang, Y. (2005). Molecular Cloning and Characterization of a Peroxiredoxin From Phanerochaete Chrysosporium. *Cell Mol. Biol. Lett.* 10, 659–668.
Karincacqv, Y., Esrefoglu, M., and Ozcan, H. (2004). Atypical Clinical Form of Cutaneous Leishmaniasis: Erysipeloid Form. Int. J. Dermatol. 43 (11), 827–829. doi: 10.1111/j.1365-4632.2004.02324.x

Lainson, R., and Shaw, J. J. (1998). “New World Leishmaniasis - Neotropical Leishmania Species” In: Cox, FE, Kreier, JP, and Wakelin, D. editors. Topley & Wilson’s Microbiology and Microbial Infections. 9th ed. London: Hodder Headline Group. p. 241–266.

Leroux, A., Fleming-Canepa, X., Aranda, A., Maugeri, D., Cazzulo, J. J., Sanchez, M. A., et al. (2006). Functional Characterization and Subcellular Localization of the Three Malate Dehydrogenase Isozymes in Leishmania Sp. Mol. Biochem. Parasitol. 149 (1), 74–85. doi: 10.1016/j.molbiopara.2006.04.010

Madeira da Silva, L., and Beverley, S. M. (2010). Expansion of the Target of Rapamycin(TOR) Kinase Family and Function in Leishmania Shows That TOR3 is Required for Acidocalcisome Biogenesis and Animal Infectivity. Proc. Natl. Acad. Sci. U.S.A. 107 (26), 11965–11970. doi: 10.1073/pnas.1004599107

Mittal, M. K., Misra, S., Ovais, M., and Goyal, N. (2005). Expression, Purification, and Characterization of Leishmania Donovani Trypanothione Reductase in Escherichia Coli. Protein Expr. Purif. 40 (2), 279–286. doi: 10.1016/j.pep.2004.12.012

Moreira, D. S., and Murta, S. M. (2016). Involvement of Nucleoside Diphosphate Kinase B and Elongation Factor 2 in Leishmania Braziliensis Antimony Resistance Phenotype. Parasit. Vectors 9 (1), 641. doi: 10.1186/s13071-016-1930-6

Mottram, C., and Coombs, G. H. (1985). Purification of Particulate Malate Dehydrogenase and Phosphoenol Pyruvate Carboxykinase From Leishmania Mexicana. Biochem. Biophys. Acta 827 pp. 310–319. doi: 10.1016/0167-4838(85)90216-x

Nagy, Z. A., Szakács, D., Boros, E., Héja, D., Vigh, E., Sándor, N., et al. (2019). Ecotin, a Microbial Inhibitor of Serine Proteases, Blocks Multiple Complement Dependent and Independent Microbialidal Activities of Human Serum. PLoS Pathog. 15 (12), e1008232. doi: 10.1371/journal.ppat.1008232

Negrão, F., Diedrich, J. K., Giorgio, S., Eberlin, M. N., and Yates, J. R. 3rd. (2019). Omidian, M., and Mapar, M. A. (2006). Functional Characterization and Subcellular Localization of the Three Malate Dehydrogenase Isozymes in Leishmania Sp. Mol. Biochem. Parasitol. 149 (1), 74–85. doi: 10.1016/j.molbiopara.2006.04.010

Pawar, H., Sathe, G., and Patoé, M. S. (2020). Genome-Wide Proteomics and Phosphoproteomics Analysis of Leishmania Sp. During Differentiation. Methods Mol. Biol. 2116, 161–176. doi: 10.1007/978-1-0716-0124-3_12

Polpitiya, A. D., Wei-Jun, Q., Negrão, F., Diedrich, J. K., Giorgio, S., Eberlin, M. N., and Yates, J. R. 3rd. (2019). Characterization of the 60 s Ribosomal Subunit Proteins La, Lb, Lf, P1, P2, L13’, L14, L18’, L20, and L38. J. Biol. Chem. 253 (3), 946–955. doi: 10.1016/S0021-9258(17)38196-6

Quaresma, P. F., de Brito, C. F. A., Rugani, J. M. N., Freire, J. M., Baptista, R. P., Moreno, E. C., et al. (2018). Distinct Genetic Profiles of Leishmania (Viannia) Braziliensis Associate With Clinical Variations in Cutaneous-Leishmaniasis Patients From an Endemic Area in Brazil. Parasitology 145 (9), 1161–1169. doi: 10.1017/S003118201800276

Qureshi, R., Jakkula, P., Sagurthi, S. R., and Qureshi, I. A. (2019). Protein Phosphatase 1 of Leishmania Donovani Exhibits Conserved Catalytic Residues and Pro-Inflammatory Response. Biochem. Biophys. Res. Commun. 516 (3), 770–776. doi: 10.1016/j.bbrc.2019.06.085

Rego, F. D., Da Rocha Lima, A., Pereira, A. A. S., Quaresma, P. F., Pascoal-Xavier, M. A., Shaw, J. J., et al. (2018). Genetic Variant Strains of Leishmania (Viannia) Brazilian Strains exhibit Distinct Biological Behaviors. Parasitol. Res. 117, 3157–3168. doi: 10.1007/s00436-018-6014-4

Rodríguez-Veja, A., Losada-Barragán, M., Berbert, L. R., Mesquita-Rodrigues, C., Bombaça, A. C. S., Menna-Barreto, R., et al. (2021). Quantitative Analysis of Proteins Secreted by Leishmania (Viannia) Brazilian Strains Associated to Distinct Clinical Manifestations of American Tegumentary Leishmaniasis. J. Proteomics 232, 104077. doi: 10.1016/j.jprot.2020.104077

Rugani, J. N., Gontijo, C. M. F., Frézard, F., Soares, R. P., and Monte-Neto, R. L. D. (2019). Antimony Resistance in Leishmania (Viannia) Brazilian Strains From Atypical Lesions Associated to Increased ARM56/ARM58 Transcripts and Reduced Drug Uptake. Mem. Inst Oswaldo Cruz 114, e190111. doi: 10.1590/0074-02760190111

Tsurugi, K., Collatz, E., Todokoro, K., Ulbrich, N., Lightfoot, H. N., and Wool, I. G. (1978). Isolation of Eukaryotic Ribosomal Proteins. Purification and Characterization of the 60 s Ribosomal Subunit Proteins La, Lb, Lf, P1, P2, L13’, L14, L18’, L20, and L38. J. Biol. Chem. 253 (3), 946–955. doi: 10.1016/S0021-9258(17)38196-6

Willie, S., Cunningham, M. L., and Fairlamb, A. H. (2004). Dual Action of Antimonial Drugs on Thiol, Redox Metabolism in the Human Pathogen Leishmania Donovani. J. Biol. Chem. 279, 39925–39932. doi: 10.1074/jbc.M405635200

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Esteves, Melo-Braga, Gorshkov, Verano-Braga, Larsen, Gontijo, Quaresma and Andreia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.